Natco和Breckenridge发射通用Pomalidomide,用于癌症和与艾滋病有关的癌症,促进获得治疗。 Natco and Breckenridge launch generic Pomalidomide for cancer and AIDS-related cancer, boosting treatment access.

Natco Pharma与Brecenridge制药公司合作,在美国推出了一种Pomalidomide胶囊的通用版本,用于治疗多种骨髓瘤和与艾滋病有关的卡波西沙尔科马,该胶囊的剂量为1至4毫克,通过特殊渠道分发。 Natco Pharma, with Breckenridge Pharmaceutical, has launched a generic version of Pomalidomide capsules in the U.S. for treating multiple myeloma and AIDS-related Kaposi sarcoma, available in 1mg to 4mg doses and distributed through specialty channels. 美国到2025年9月的销售额估计为32亿美元,根据林业发展局的规则,该药物受180天的共同独家经营保护。 The drug, which had an estimated $3.2 billion in U.S. sales through September 2025, is protected by 180 days of shared exclusivity under FDA rules. 该启动旨在改进获得特殊癌症治疗的机会。 The launch aims to improve access to specialty cancer treatments.